To test a requirement for CD11c+ cells, in particular cDC1, on adoptively transferred tumor-specific T cells, we established a model of adoptive cell therapy (ACT) in which CD8+ T cells were engineered to express the anti-melanoma TCR, which recognizes TRP-2181–188 presented by H2-Kb.20 This evidence concerns the gene CD8A and melanoma.